CRISPR and CAS Gene Market Upcoming Trends, Demand and Analysis Till 2026
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated (Cas) genes are essential for the adaptive immunity in few bacteria and archaea, enabling the organisms to respond to and to eliminate invading genetic material. These gene editing tools are extensively used in agriculture and food security.
Request For a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/2598
Many food and agricultural organizations are working on receiving license for using CRISPR and CAS gene technology for creating novel products in food and agriculture business. For instance, in September 2016, agrochemical and agricultural biotechnology corporation Monsanto secured a worldwide non-exclusive license agreement for agricultural applications of CRISPR technology from the Broad Institute. CRISPR and CAS genes are also used in treating a number of diseases such as cancer, blood disorders, AIDS, and genetic disorders such as cystic fibrosis, Huntington’s etc.
Increasing prevalence of genetic disorders such as Down’s syndrome, sickle cell anaemia, and Huntington’s disease worldwide is highly contributing to the market growth of CRISPR and CAS gene market, as many genetic disabilities can be corrected using this gene editing technology. According to National Health Service (NHS) U.K. 2018 report, the highest rate of Huntington’s disease in the United Kingdom is 12 per 100,000 people. Also, in the U.S., an estimated 10 per 100,000 have the faulty Huntington’s gene and live either waiting for symptoms to begin or live/struggle with the disease.
Government bodies are taking initiatives for developing treatment of Huntington’s disease. For instance, in 2016, US-based Company Addgene has developed the KamiCas9, a version of CRISPR-Cas9 that includes a ‘self-inactivating’ KamiCas9 system for the editing of CNS disease genes for treatment of Huntington’s disease.
Increasing Demand for Clinical Trials Coupled with Increasing Research & Development in CRISPR and CAS Gene therapy is expected to Drive Growth of the CRISPR and CAS Gene Market
Increasing research & development and demand for clinical trials for development of new technologies in CRISPR and CAS gene therapy for treatment of cancer is one of the major driving factor. For instance, The Parker Institute for Cancer Immunotherapy, a non-profit organization formed in April 2016, with a US$ 250 million grant from the Parker Foundation, agreed to sponsor the first in-human clinical trials of CRISPR-enabled technology targeting three types of cancer. The trial, led by the University of Pennsylvania, will use CRISPR-modified T-cells, a part of the human immune system, to treat myeloma, melanoma, and sarcoma. The trial was commenced in 2017.
Therefore, increasing research on CRISPR and CAS gene market is expected to create a favorable environment for CRISPR and CAS gene market growth in the near future.
CRISPR and CAS Gene Market – Competitive Landscape
Key players operating in the global CRISPR and CAS Gene market include Caribou Biosciences Inc., CRISPR Therapeutics, Mirus Bio LLC, Editas Medicine, Takara Bio Inc., Synthego, Thermo Fisher Scientific, Inc., GenScript, Addgene, Merck KGaA (Sigma-Aldrich), Integrated DNA Technologies, Inc., Transposagen Biopharmaceuticals, Inc., OriGene Technologies, Inc., New England Biolabs, Dharmacon, Cellecta, Inc., Agilent Technologies, and Applied StemCell, Inc.
Purchase This Premium Report : https://www.coherentmarketinsights.com/insight/buy-now/2598
- Global CRISPR and CAS Gene Market, By Product Type:
- Vector-based Cas
- DNA-free Cas
- Global CRISPR and CAS Gene Market, By Application:
- Genome Engineering
- Disease models
- Functional Genomics
- Other Applications
- Global CRISPR and CAS Gene Market, By End User:
- Biotechnology and Pharmaceutical Companies
- Academic & Government Research Institutes
- Contract Research Organizations
CRISPR and CAS Gene Market – Regional Insights
On the basis of region, the global CRISPR and CAS Gene Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global CRISPR and CAS Gene market, owing to increasing number of the Food and Drug Administration (FDA) approval for clinical trial. For instance, in October 2018, CRISPR Therapeutics and Vertex Pharmaceuticals’ highly anticipated gene-editing trial, which was allowed for the first time to discover, develop, and commercialize new breakthrough therapeutics to cure blood disorders and congenital heart disease using the CRISPR/Cas9 technology in the U.S. In January 2019, CRISPR Therapeutics and Vertex Pharmaceuticals’ have been granted Fast Track Designation to CTX001 for the treatment of sickle cell disease (SCD) by FDA. CTX001 is an investigational, autologous, gene-edited hematopoietic stem cell therapy for patients suffering from severe hemoglobinopathies.
Asia Pacific is expected to foresee a rapid growth in the CRISPR and CAS Gene market over the forecast period. The market in Asia Pacific is expected to gain momentum during the forecast period, owing to rise in the demand of CRISPR and CAS gene therapy especially in research activities. For instance, in May 2018 researchers at Kobe University in Japan successfully destroyed and deleted the regulatory genes of HIV-1 using the genome editing system CRISPR/Cas9, thereby successfully blocking the production of HIV-1 by infected cells.